Richard Peters

Insider Reports History

Entity
Individual
Location
Merrimack Pharmaceuticals, Inc., One Kendall Square, Suite B7201, Cambridge, Massachusetts
Signature
/s/ John Hamill, as Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Richard Peters:

Stock Role Class Num Shares Value Price $ Report Date Ownership
KINETA, INC./DE Director Common Stock 88.1 K $396 K $4.50 Dec 16, 2022 Direct
Aprea Therapeutics, Inc. Director Common Stock 2.07 K $15.1 K $7.29 Jun 20, 2024 Direct
KINETA, INC./DE Director Stock Option (Right to Buy) 12.5 K Apr 12, 2023 Direct
Aprea Therapeutics, Inc. Director Stock Options (Right to Buy) 4.19 K Jun 20, 2024 Direct

Insider Reports Filed by Richard Peters

Symbol Company Period Transactions Value $ Form Type Date Filed Role
APRE Aprea Therapeutics, Inc. Jun 20, 2024 2 $0 4 Jun 21, 2024 Director
APRE Aprea Therapeutics, Inc. Aug 23, 2023 2 $0 4 Aug 24, 2023 Director
KA KINETA, INC./DE Apr 12, 2023 2 $0 4 Apr 14, 2023 Director
KA KINETA, INC./DE Dec 16, 2022 1 -$3.59 K 4 Dec 20, 2022 Director
KA YUMANITY THERAPEUTICS, INC. Dec 2, 2022 1 -$18.4 K 4 Dec 6, 2022 President and CEO, Director
APRE Aprea Therapeutics, Inc. Jul 28, 2022 2 $0 4 Aug 1, 2022 Director
KA YUMANITY THERAPEUTICS, INC. Jul 5, 2022 1 -$8.48 K 4 Jul 6, 2022 President and CEO, Director
KA YUMANITY THERAPEUTICS, INC. Jun 3, 2022 1 -$12.2 K 4 Jun 6, 2022 President and CEO, Director
KA YUMANITY THERAPEUTICS, INC. Mar 28, 2022 1 -$19.8 K 4 Mar 30, 2022 President and CEO, Director
KA YUMANITY THERAPEUTICS, INC. Dec 1, 2021 1 $0 4 Dec 3, 2021 President and CEO, Director
KA YUMANITY THERAPEUTICS, INC. Jul 2, 2021 2 -$50.2 K 4 Jul 7, 2021 President and CEO, Director
APRE Aprea Therapeutics, Inc. Jun 30, 2021 2 $0 4 Jul 1, 2021 Director